These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36102633)

  • 41. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
    Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
    Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
    Nam MH; Hsieh YY; Chen BJ
    Pathology; 2022 Aug; 54(5):634-636. PubMed ID: 34872752
    [No Abstract]   [Full Text] [Related]  

  • 43. A subtype of aggressive B-cell lymphoma with an unusual presentation of effusion without masses.
    Kamihira S; Jiann C; Uemura A; Tsuruda K; Hasegawa H; Sugahara K; Yamada Y
    Leuk Lymphoma; 2006 Sep; 47(9):1991-3. PubMed ID: 17065024
    [No Abstract]   [Full Text] [Related]  

  • 44. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
    Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
    Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
    Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coexistence of MYC/BCL2 double-hit of t(8;14)(q24;q32) and t(14;18)(q32;q21) and that of t(8;22)(q24;q11) and t(14;18) in advanced-stage high-grade B cell lymphoma.
    Takeoka K; Nakagawa M; Kishimori C; Fukutsuka K; Maekawa F; Hayashida M; Ohno H
    Ann Hematol; 2021 Dec; 100(12):3043-3045. PubMed ID: 32895753
    [No Abstract]   [Full Text] [Related]  

  • 47. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EBV
    Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
    Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cutaneous Involvement in a High Grade B-Cell Lymphoma With Rearrangement of MYC, BCL2, and BCL6 Transformed From Follicular Lymphoma.
    Martinez-Mera C; Herrero-Moyano M; López-Elzaurdia C; Loscertales J; Aragües M
    Am J Dermatopathol; 2019 Jan; 41(1):80-82. PubMed ID: 30608910
    [No Abstract]   [Full Text] [Related]  

  • 50. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
    Drexler HG; Eberth S; Nagel S; MacLeod RA
    Leuk Lymphoma; 2016 May; 57(5):1015-20. PubMed ID: 26727417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
    Krull JE; Wenzl K; Hartert KT; Manske MK; Sarangi V; Maurer MJ; Larson MC; Nowakowski GS; Ansell SM; McPhail E; Habermann TM; Link BK; King RL; Cerhan JR; Novak AJ
    Blood Cancer J; 2020 Nov; 10(11):117. PubMed ID: 33168821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Menter T; Medani H; Ahmad R; Flora R; Trivedi P; Reid A; Naresh KN
    Br J Haematol; 2017 Nov; 179(4):681-684. PubMed ID: 27447126
    [No Abstract]   [Full Text] [Related]  

  • 53. High grade B-cell lymphoma with
    Ferrari A; Arniani S; Crescenzi B; Ascani S; Flenghi L; Pierini V; Moretti M; Beacci D; Romoli S; Bardelli V; Calistri D; Martinelli G; Mecucci C; La Starza R
    Leuk Lymphoma; 2022 Jun; 63(6):1356-1362. PubMed ID: 35045798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
    Rosenthal A; Younes A
    Blood Rev; 2017 Mar; 31(2):37-42. PubMed ID: 27717585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted next generation sequencing reveals high mutation frequency of
    Evrard SM; Péricart S; Grand D; Amara N; Escudié F; Gilhodes J; Bories P; Traverse-Glehen A; Dubois R; Brousset P; Parrens M; Laurent C
    Haematologica; 2019 Apr; 104(4):e154-e157. PubMed ID: 30309852
    [No Abstract]   [Full Text] [Related]  

  • 56. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
    Gerhard-Hartmann E; Rosenwald A
    Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification.
    Szumera-Ciećkiewicz A; Rymkiewicz G; Grygalewicz B; Jesionek-Kupnicka D; Gruchała A; Ziarkiewicz-Wróblewska B; Gałązka K; Reszeć J; Borg K; Prochorec-Sobieszek M
    Pol J Pathol; 2018; 69(1):1-19. PubMed ID: 29895122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y; Zhang X
    Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.